Citations (152)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (26)
Andrea Haake, Kevin Nguyen, Lauren Friedman, Binu Chakkamparambil & George T Grossberg. (2020) An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opinion on Drug Safety 19:2, pages 147-157.
Read now
Read now
Hamid Reza Amanatkar & George Thomas Grossberg. (2014) Transdermal rivastigmine in the treatment of Alzheimer’s disease: current and future directions. Expert Review of Neurotherapeutics 14:10, pages 1119-1125.
Read now
Read now
Filip Zemek, Lucie Drtinova, Eugenie Nepovimova, Vendula Sepsova, Jan Korabecny, Jiri Klimes & Kamil Kuca. (2014) Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opinion on Drug Safety 13:6, pages 759-774.
Read now
Read now
Secundino López-Pousa & Francisco Javier Arranz. (2013) Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice. Patient Preference and Adherence 7, pages 47-54.
Read now
Read now
Takemi Kimura & Junichi Takamatsu. (2013) Two cases of Alzheimer’s disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil. Neuropsychiatric Disease and Treatment 9, pages 49-53.
Read now
Read now
Serge Gauthier, Alain Robillard, Sharon Cohen, Sandra Black, John Sampalis, Diane Colizza, Frederica de Takacsy & Robyn Schecter. (2013) Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE study. Current Medical Research and Opinion 29:8, pages 989-1000.
Read now
Read now
Åsa K Wallin, Carina Wattmo & Lennart Minthon. (2011) Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting. Neuropsychiatric Disease and Treatment 7, pages 565-576.
Read now
Read now
Ralf Ihl, Lutz Frölich, Bengt Winblad, Lon Schneider, Alistair Burns & Hans-Jürgen Möller. (2011) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias. The World Journal of Biological Psychiatry 12:1, pages 2-32.
Read now
Read now
Michael Shanks, Miia Kivipelto, Roger Bullock & Roger Lane. (2009) Cholinesterase inhibition: is there evidence for disease-modifying effects?. Current Medical Research and Opinion 25:10, pages 2439-2446.
Read now
Read now
Norifumi Tsuno. (2009) Donepezil in the treatment of patients with Alzheimer’s disease. Expert Review of Neurotherapeutics 9:5, pages 591-598.
Read now
Read now
Laurent Lecanu, Laurent Tillement, Georges Rammouz, Jean Paul Tillement, Janet Greeson & Vassilios Papadopoulos. (2009) Caprospinol: moving from a neuroactive steroid to a neurotropic drug. Expert Opinion on Investigational Drugs 18:3, pages 265-276.
Read now
Read now
Hind T Hatoum, Simu K Thomas, Swu-Jane Lin, Roger Lane & Roger Bullock. (2009) Predicting time to nursing home placement based on activities of daily living scores – a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil. Journal of Medical Economics 12:2, pages 98-103.
Read now
Read now
Claudie Charbonneau, Fadi Massoud, Marc Dorais & Jacques LeLorier. (2008) A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes. Current Medical Research and Opinion 24:12, pages 3287-3294.
Read now
Read now
Ging-Yuek Robin Hsiung & Howard H Feldman. (2008) Pharmacological treatment in moderate-to-severe Alzheimer's disease. Expert Opinion on Pharmacotherapy 9:15, pages 2575-2582.
Read now
Read now
Richard A Hansen, Gerald Gartlehner, Aaron P Webb, Laura C Morgan, Charity G Moore & Daniel E Jonas. (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clinical Interventions in Aging 3:2, pages 211-225.
Read now
Read now
David L. Eaton, Robert B. Daroff, Herman Autrup, James Bridges, Patricia Buffler, Lucio G. Costa, Joseph Coyle, Guy McKhann, William C. Mobley, Lynn Nadel, Diether Neubert, Rolf Schulte-Hermann & Peter S. Spencer. (2008) Review of the Toxicology of Chlorpyrifos With an Emphasis on Human Exposure and Neurodevelopment. Critical Reviews in Toxicology 38:sup2, pages 1-125.
Read now
Read now
Roberta Annicchiarico, Alessia Federici, Carla Pettenati & Carlo Caltagirone. (2007) Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life. Therapeutics and Clinical Risk Management 3:6, pages 1113-1123.
Read now
Read now
Thomas Müller. (2007) Rivastigmine in the treatment of patients with Alzheimer’s disease. Neuropsychiatric Disease and Treatment 3:2, pages 211-218.
Read now
Read now
David B Hogan. (2007) Progress update: Pharmacological treatment of Alzheimer’s disease. Neuropsychiatric Disease and Treatment 3:5, pages 569-578.
Read now
Read now
Ramón Cacabelos. (2007) Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiatric Disease and Treatment 3:3, pages 303-333.
Read now
Read now
Tony Mets, Maurits Vandewoude, Jean Jacquy, Anne Deblander, Karen MacDonald, Anne Sloesen & Ivo Abraham. (2007) Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease:the Belgian FExT study. Current Medical Research and Opinion 23:10, pages 2485-2501.
Read now
Read now
N. Mirhaghani, L. Higgins, A. Sajjadi & S. Curran. (2007) Recent developments in the treatment of Alzheimer's disease. Journal of Care Services Management 2:1, pages 28-39.
Read now
Read now
K. Venkatesh, R. Bullock & A. Akbas¸. (2007) Strategies to improve tolerability of rivastigmine: a case series. Current Medical Research and Opinion 23:1, pages 93-95.
Read now
Read now
Serge Gauthier, Angela Juby, Lidia Morelli, Bonita Rehel & Robyn Schecter. (2006) A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD:the EXTEND Study. Current Medical Research and Opinion 22:11, pages 2251-2265.
Read now
Read now
Roger Bullock, Howard Bergman, Jacques Touchon, Giuseppe Gambina, Yunsheng He, Jennifer Nagel & Roger Lane. (2006) Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Current Medical Research and Opinion 22:3, pages 483-494.
Read now
Read now
Jacques Touchon, Howard Bergman, Roger Bullock, Günter Rapatz, Jennifer Nagel & Roger Lane. (2006) Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Current Medical Research and Opinion 22:1, pages 49-59.
Read now
Read now
Articles from other publishers (126)
Jared C. Roach, Molly K. Rapozo, Junko Hara, Gwênlyn Glusman, Jennifer Lovejoy, William R. Shankle & Leroy Hood. (2023) A Remotely Coached Multimodal Lifestyle Intervention for Alzheimer’s Disease Ameliorates Functional and Cognitive Outcomes. Journal of Alzheimer's Disease 96:2, pages 591-607.
Crossref
Crossref
Gabbie E. Portlock, Matthew D. Smith, Eveline P. van Poelgeest & Tomas James Welsh. (2023) Therapeutic dilemmas: cognitive enhancers and risk of falling in older adults—a clinical review. European Geriatric Medicine 14:4, pages 721-732.
Crossref
Crossref
Zeinab Mahmoud, Lamia W. Mohamed, Khaled O. Mohamed, Hadeer S. Sayed, May A. Abd El Fattah & Afaf El-Malah. (2023) New tetracyclic systems integrated thienopyridine scaffold as an anti-dementia lead: in silico study and biological screening. Medicinal Chemistry Research 32:3, pages 571-586.
Crossref
Crossref
F. Trotta, L. Biscetti & A. Cherubini. 2023. Optimizing Pharmacotherapy in Older Patients. Optimizing Pharmacotherapy in Older Patients
269
287
.
D. P. Devanand & R. Fremont. 2020. Tasman’s Psychiatry. Tasman’s Psychiatry
1
42
.
Sara Rose Dunlop, Ivan Ayala, Callen Spencer, Margaret E Flanagan, Marek-Marsel Mesulam, Tamar Gefen & Changiz Geula. (2022) Resistance of Basal Forebrain Cholinergic Neurons to TDP-43 Proteinopathy in Primary Progressive Aphasia. Journal of Neuropathology & Experimental Neurology 81:11, pages 910-919.
Crossref
Crossref
Ping-Tao Tseng, Bing-Yan Zeng, Yen-Wen Chen, Chun-Pai Yang, Kuan-Pin Su, Tien-Yu Chen, Yi-Cheng Wu, Yu-Kang Tu, Pao-Yen Lin, Andre F. Carvalho, Brendon Stubbs, Yutaka J. Matsuoka, Dian-Jeng Li, Chih-Sung Liang, Chih-Wei Hsu, Cheuk-Kwan Sun, Yu-Shian Cheng, Pin-Yang Yeh & Yow-Ling Shiue. (2022) The Dose and Duration-dependent Association between Melatonin Treatment
and Overall Cognition in Alzheimer’s Dementia: A Network Meta-
Analysis of Randomized Placebo-Controlled Trials. Current Neuropharmacology 20:10, pages 1816-1833.
Crossref
Crossref
Julien Delrieu. 2022. Pathy's Principles and Practice of Geriatric Medicine. Pathy's Principles and Practice of Geriatric Medicine
794
807
.
Germán Plascencia-Villa & George Perry. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
34
63
.
Feng Zhang, Xinyao Liu, Yufei Liu, Yanjiang Wang & Weidong Le. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2677
2707
.
Sandesh P. Kamdi, Hemant R. Badwaik, Amit Raval, Ajazuddin & Kartik T. Nakhate. (2021) Ameliorative potential of phloridzin in type 2 diabetes-induced memory deficits in rats. European Journal of Pharmacology 913, pages 174645.
Crossref
Crossref
Changiz Geula, Sara R. Dunlop, Ivan Ayala, Allegra S. Kawles, Margaret E. Flanagan, Tamar Gefen & Marek‐Marsel Mesulam. (2021) Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance. Journal of Neurochemistry 158:6, pages 1394-1411.
Crossref
Crossref
Anaïs Vignon, Lucie Salvador-Prince, Sylvain Lehmann, Véronique Perrier & Joan Torrent. (2021) Deconstructing Alzheimer’s Disease: How to Bridge the Gap between Experimental Models and the Human Pathology?. International Journal of Molecular Sciences 22:16, pages 8769.
Crossref
Crossref
Jinsha Liu, Joey Paolo Ting, Shams Al-Azzam, Yun Ding & Sepideh Afshar. (2021) Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. International Journal of Molecular Sciences 22:6, pages 2805.
Crossref
Crossref
Chantal Vidal & Li Zhang. (2021) An Analysis of the Neurological and Molecular Alterations Underlying the Pathogenesis of Alzheimer’s Disease. Cells 10:3, pages 546.
Crossref
Crossref
Jiangtao Zhang, Jianan Cheng & Hua Yang. (2021) Effects of Rivastigmine on Brain Functional Networks in Patients With Alzheimer Disease Based on the Graph Theory. Clinical Neuropharmacology 44:1, pages 9-16.
Crossref
Crossref
Md. Sahab Uddin, Abdullah Al Mamun, Md. Tanvir Kabir, Ghulam Md Ashraf, May N. Bin-Jumah & Mohamed M. Abdel-Daim. (2020) Multi-Target Drug Candidates for Multifactorial Alzheimer’s Disease: AChE and NMDAR as Molecular Targets. Molecular Neurobiology 58:1, pages 281-303.
Crossref
Crossref
Mohd Ahmar Rauf, Katyayani Tatiparti & Arun K. Iyer. 2021. Autism Spectrum Disorder and Alzheimer's Disease. Autism Spectrum Disorder and Alzheimer's Disease
215
237
.
Vesna Jelic & Bengt Winblad. 2021. Management of Patients with Dementia. Management of Patients with Dementia
73
104
.
Katyayani Tatiparti, Samaresh Sau, Mohd Ahmar Rauf & Arun K. Iyer. (2020) Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease. Drug Discovery Today 25:12, pages 2110-2129.
Crossref
Crossref
Luminita Capatina, Razvan Stefan Boiangiu, Gabriela Dumitru, Edoardo Marco Napoli, Giuseppe Ruberto, Lucian Hritcu & Elena Todirascu-Ciornea. (2020) Rosmarinus officinalis Essential Oil Improves Scopolamine-Induced Neurobehavioral Changes via Restoration of Cholinergic Function and Brain Antioxidant Status in Zebrafish (Danio rerio). Antioxidants 9:1, pages 62.
Crossref
Crossref
Miguel Gago, Alvaro Machado & Sofia Rocha. 2020. Handbook of Innovations in Central Nervous System Regenerative Medicine. Handbook of Innovations in Central Nervous System Regenerative Medicine
79
124
.
Feng Zhang, Xinyao Liu, Yufei Liu, Yanjiang Wang & Weidong Le. 2019. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
31
.
Elizabeth Joe & John M Ringman. (2019) Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. BMJ, pages l6217.
Crossref
Crossref
Afaf El-Malah, Ahmed I.Y. Abouelatta, Zeinab Mahmoud & Heba Hamed Salem. (2019) New cyclooctathienopyridine derivatives in the aim of discovering better Anti-Alzheimer's agents. Journal of Molecular Structure 1196, pages 162-168.
Crossref
Crossref
Pei-Pei Liu, Yi Xie, Xiao-Yan Meng & Jian-Sheng Kang. (2019) History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduction and Targeted Therapy 4:1.
Crossref
Crossref
Steve Pedrini, Mike Morici & Ralph N. Martins. 2019. Neurodegeneration and Alzheimer's Disease. Neurodegeneration and Alzheimer's Disease
391
442
.
Peter Swann & John T. O’Brien. (2018) Management of visual hallucinations in dementia and Parkinson’s disease. International Psychogeriatrics 31:6, pages 815-836.
Crossref
Crossref
Marieke J. H. J. Dekker, Jacoline C. Bouvy, Diana O'Rourke, Robin Thompson, Amr Makady, Pall Jonsson & Christine C. Gispen-de Wied. (2019) Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease. Frontiers in Medicine 6.
Crossref
Crossref
M.-Marsel MesulamNava LalehzariFarzan RahmaniDaniel OhmRyan ShahidehpourGaram KimTamar GefenSandra WeintraubEileen BigioChangiz Geula. (2019) Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology. Neurology 92:14.
Crossref
Crossref
Kazuki Terada, Keisuke Migita, Yukari Matsushima & Chiaki Kamei. (2019) Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders. Neural Regeneration Research 14:11, pages 1893.
Crossref
Crossref
Sandipan Bhattacharjee, Asad E. Patanwala, Wei‐Hsuan Lo‐Ciganic, Daniel C. Malone, Jeannie K. Lee, Shannon M. Knapp, Terri Warholak & William J. Burke. (2019) Alzheimer's disease medication and risk of all‐cause mortality and all‐cause hospitalization: A retrospective cohort study. Alzheimer's & Dementia: Translational Research & Clinical Interventions 5:1, pages 294-302.
Crossref
Crossref
Armin von Gunten, Eduardo Nogueira, Henk Parmentier & Irênio Gomes. 2019. Primary Care Mental Health in Older People. Primary Care Mental Health in Older People
251
298
.
Kazuki Terada, Keisuke Migita, Yukari Matsushima, Yumi Sugimoto, Chiaki Kamei, Taichi Matsumoto, Masayoshi Mori, Kazuhisa Matsunaga, Jiro Takata & Yoshiharu Karube. (2018) Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. PLOS ONE 13:12, pages e0209250.
Crossref
Crossref
Daniela Volpato & Ulrike Holzgrabe. (2018) Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer’s Disease. Molecules 23:12, pages 3230.
Crossref
Crossref
John M. Nolan, Riona Mulcahy, Rebecca Power, Rachel Moran & Alan N. Howard. (2018) Nutritional Intervention to Prevent Alzheimer’s Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined. Journal of Alzheimer's Disease 64:2, pages 367-378.
Crossref
Crossref
Oya Unsal-Tan, Keriman Ozadali-Sari, Beyza Ayazgok, Tuba Tüylü Küçükkılınç & Ayla Balkan. (2017) Novel 2-Arylbenzimidazole derivatives as multi-targeting agents to treat Alzheimer’s disease. Medicinal Chemistry Research 26:7, pages 1506-1515.
Crossref
Crossref
Jianping Jia, Serge Gauthier, Sarah Pallotta, Yong Ji, Wenshi Wei, Shifu Xiao, Dantao Peng, Qihao Guo, Liyong Wu, Shengdi Chen, Weihong Kuang, Junjian Zhang, Cuibai Wei & Yi Tang. (2017) Consensus‐based recommendations for the management of rapid cognitive decline due to Alzheimer's disease. Alzheimer's & Dementia 13:5, pages 592-597.
Crossref
Crossref
Jin Cao, Yinshan Tang, Yujie Li, Kai Gao, Xudong Shi & Zhigang Li. (2017) Behavioral Changes and Hippocampus Glucose Metabolism in APP/PS1 Transgenic Mice via Electro-acupuncture at Governor Vessel Acupoints. Frontiers in Aging Neuroscience 09.
Crossref
Crossref
Barbara J. Messinger-Rapport, Milta O. Little, John E. Morley & Julie K. Gammack. (2016) Clinical Update on Nursing Home Medicine: 2016. Journal of the American Medical Directors Association 17:11, pages 978-993.
Crossref
Crossref
Louis De Beaumont, Sandra Pelleieux, Louise Lamarre-Théroux, Doris Dea & Judes Poirier. (2016) Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer’s Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. Journal of Alzheimer's Disease 54:3, pages 913-922.
Crossref
Crossref
V Khoirunisa, F Rusydi, H Kasai, A G Gandaryus & H K Dipojono. (2016) A first principle study on the interaction between acetylcholinesterase and acetylcholine, and also rivastigmine in alzheimer's disease case. Journal of Physics: Conference Series 739, pages 012136.
Crossref
Crossref
Hisanori Kobayashi, Takashi Ohnishi, Ryoko Nakagawa & Kazutake Yoshizawa. (2016) The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis. International Journal of Geriatric Psychiatry 31:8, pages 892-904.
Crossref
Crossref
Brandy R. Matthews. 2016. The Behavioral Neurology of Dementia. The Behavioral Neurology of Dementia
123
142
.
Andrew Fedor, Fawn Walter, Joel W. Hughes & John Gunstad. (2016) Exercise and Cognitive Function: Increased Fitness Improves Cognition in Older Adults and Those with Chronic Medical Conditions. Journal of Clinical Exercise Physiology 5:2, pages 21-27.
Crossref
Crossref
Kosuke Matsuzono, Nozomi Hishikawa, Yoshiki Takao, Yosuke Wakutani, Toru Yamashita, Kentaro Deguchi & Koji Abe. (2015)
Combination benefit of cognitive rehabilitation plus donepezil for
A
lzheimer's disease patients
. Geriatrics & Gerontology International 16:2, pages 200-204.
Crossref
Crossref
Andrew E. Budson & Paul R. Solomon. 2016. Memory Loss, Alzheimer's Disease, and Dementia. Memory Loss, Alzheimer's Disease, and Dementia
160
173
.
Takashi Kudo, Kenneth L. Davis, Rafael Blesa Gonzalez & David George WilkinsonKenneth L. Davis. 2016. Practical Pharmacology for Alzheimer’s Disease. Practical Pharmacology for Alzheimer’s Disease
35
61
.
Jacqueline S Birks, Lee-Yee Chong & John Grimley Evans. (2015) Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Alireza Atri & Theodore A. Stern. (2015) Psychopharmacologic Agents to Enhance Cognition in Alzheimer’s Disease. Psychiatric Annals 45:7.
Crossref
Crossref
Yun-Ping Chang, Chiu-Hsien Yang, Mei-Chuan Chou, Chun-Hung Chen & Yuan-Han Yang. (2014) Clinical Compliance of Donepezil in Treating Alzheimer’s Disease in Taiwan. American Journal of Alzheimer's Disease & Other Dementiasr 30:4, pages 346-351.
Crossref
Crossref
Edward Chia‐Cheng Lai, Monera B. Wong, Isao Iwata, Yinghong Zhang, Cheng‐Yang Hsieh, Yea‐Huei Kao Yang & Soko Setoguchi. (2015) Risk of Pneumonia in New Users of Cholinesterase Inhibitors for Dementia. Journal of the American Geriatrics Society 63:5, pages 869-876.
Crossref
Crossref
Soichiro Shimizu, Hidekazu Kanetaka, Daisuke Hirose, Hirohumi Sakurai & Haruo Hanyu. (2015) Differential Effects of Acetylcholinesterase Inhibitors on Clinical Responses and Cerebral Blood Flow Changes in Patients with Alzheimer's Disease: A 12-Month, Randomized, and Open-Label Trial. Dementia and Geriatric Cognitive Disorders Extra 5:1, pages 135-146.
Crossref
Crossref
Jacqueline S Birks & John Grimley Evans. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
D. P. Devanand. 2015. Psychiatry. Psychiatry
2236
2260
.
Beate Mueller & Georg Adler. (2015) Prevalence of Wild-Type Butyrylcholinesterase Genotype in Patients with Alzheimer’s Dementia. World Journal of Neuroscience 05:03, pages 175-179.
Crossref
Crossref
Pekka S. Miettinen, Anne M. Jauhiainen, Ina M. Tarkka, Maija Pihlajamäki, Heidi Gröhn, Eini Niskanen, Tuomo Hänninen, Ritva Vanninen & Hilkka Soininen. (2015) Long-Term Response to Cholinesterase Inhibitor Treatment Is Related to Functional MRI Response in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders 40:5-6, pages 243-255.
Crossref
Crossref
Yong Kyun Kim, Kil-Byung Lim, Sang Chul Lee, Jin-Woo Park, Hong-Jae Lee, Bum Sun Kwon & Ho Jun Lee. (2014) Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease. Dementia and Geriatric Cognitive Disorders Extra 4:3, pages 395-401.
Crossref
Crossref
James E. Frampton. (2014) Rivastigmine Transdermal Patch 13.3 mg/24 h: A Review of Its Use in the Management of Mild to Moderate Alzheimer’s Dementia. Drugs & Aging 31:8, pages 639-649.
Crossref
Crossref
Peter Nordstr?m, Dorota Religa, Anders Wimo, Bengt Winblad & Maria Eriksdotter. (2013) The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. European Heart Journal 34:33, pages 2585-2591.
Crossref
Crossref
Koteswara Rao Valasani, Michael O. Chaney, Victor W. Day & Shirley ShiDu Yan. (2013) Acetylcholinesterase Inhibitors: Structure Based Design, Synthesis, Pharmacophore Modeling, and Virtual Screening. Journal of Chemical Information and Modeling 53:8, pages 2033-2046.
Crossref
Crossref
Sachiko Satoh, Mutsuko Kajiwara, Emi Kiyokawa, Yoshiko Toukairin, Masahiko Fujii & Hidetada Sasaki. (2013)
Rivastigmine patch and massage for
A
lzheimer's disease patients
. Geriatrics & Gerontology International 13:2, pages 515-516.
Crossref
Crossref
Roger M. Lane & Yunsheng He. (2012) Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype. Alzheimer's & Dementia 9:2.
Crossref
Crossref
Françoise Forette. (2012) Les enjeux de la prévention. Gérontologie et société vol. 35 / HS n° 1:5, pages 27-40.
Crossref
Crossref
Daniel Rodríguez, Francesc Formiga, Isabel Fort, María José Robles, Elena Barranco & Dolors Cubí. (2012) Tratamiento farmacológico de la demencia: cuándo, cómo y hasta cuándo. Recomendaciones del Grupo de Trabajo de Demencias de la Sociedad Catalana de Geriatría y Gerontología. Revista Española de Geriatría y Gerontología 47:5, pages 228-233.
Crossref
Crossref
Darren Cotterell & Martin Brown. 2012. Essential Evidence-Based Psychopharmacology. Essential Evidence-Based Psychopharmacology
262
277
.
Krista Lanctôt, Ida Kircanski, Sarah Chau & Nathan Herrmann. 2012. Alzheimer's Disease. Alzheimer's Disease
117
161
.
YoungSoon YangHyun Duk YangYun-Jung HongJung Eun KimMoon-Ho ParkHae Ri NaIl-Woo HanSangYun Kim. (2012) Activities of Daily Living and Dementia. Dementia and Neurocognitive Disorders 11:2, pages 29.
Crossref
Crossref
Jeffrey Cummings, Lutz Froelich, Sandra E. Black, Serge Bakchine, Giuseppe Bellelli, José L. Molinuevo, Reto W. Kressig, Pamela Downs, Angelika Caputo & Christine Strohmaier. (2012)
Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm
2
) in Alzheimers Disease
. Dementia and Geriatric Cognitive Disorders 33:5, pages 341-353.
Crossref
Crossref
Camryn Berk & Marwan Sabbagh. (2012) Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease. International Journal of Alzheimer's Disease 2012, pages 1-4.
Crossref
Crossref
V. Papadopoulos & L. Lecanu. (2011)
Caprospinol: Discovery of a Steroid Drug Candidate to Treat Alzheimer’s Disease Based on 22
R
‐Hydroxycholesterol Structure and Properties
. Journal of Neuroendocrinology 24:1, pages 93-101.
Crossref
Crossref
Nathan Herrmann, Sarah A. Chau, Ida Kircanski & Krista L. Lanctôt. (2011) Current and Emerging Drug Treatment Options for Alzheimerʼs Disease. Drugs 71:15, pages 2031-2065.
Crossref
Crossref
Clive Ballard, Zunera Kahn & Anne Corbett. (2011) Treatment of Dementia with Lewy Bodies and Parkinsonʼs Disease Dementia. Drugs & Aging 28:10, pages 769-777.
Crossref
Crossref
Balázs Nagy, Alan Brennan, Ágnes Brandtmüller, Simu K. Thomas, Sean D. Sullivan & Ron Akehurst. (2011) Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. International Journal of Geriatric Psychiatry 26:5, pages 483-494.
Crossref
Crossref
. (2012) Cognitive enhancers provide some benefits in patients with moderate to severe Alzheimer’s disease. Drugs & Therapy Perspectives 27:4, pages 9-12.
Crossref
Crossref
Julien Delrieu, Antoine Piau, Céline Caillaud, Thierry Voisin & Bruno Vellas. (2011) Managing Cognitive Dysfunction through the Continuum of Alzheimerʼs Disease. CNS Drugs 25:3, pages 213-226.
Crossref
Crossref
Gary Small & Roger Bullock. (2010) Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. Alzheimer's & Dementia 7:2, pages 177-184.
Crossref
Crossref
Carina Wattmo, Åsa K Wallin, Elisabet Londos & Lennart Minthon. (2011) Predictors of long-term cognitive outcome in Alzheimer's disease. Alzheimer's Research & Therapy 3:4, pages 23.
Crossref
Crossref
X. A. Alvarez, R. Cacabelos, C. Sampedro, M. Aleixandre, C. Linares, E. Granizo, E. Doppler & H. Moessler. (2011) Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. European Journal of Neurology 18:1, pages 59-68.
Crossref
Crossref
Andrew E. Budson & Paul R. Solomon. 2011. Memory Loss. Memory Loss
166
183
.
Martin Steinberg & Constantine G. Lyketsos. 2010. Principles and Practice of Geriatric Psychiatry. Principles and Practice of Geriatric Psychiatry
304
311
.
Jaclyn Cappell, Nathan Herrmann, Stephen Cornish & Krista L. Lanctôt. (2010) The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease. CNS Drugs 24:11, pages 909-927.
Crossref
Crossref
Françoise Forette & Jean-Jacques Hauw. (2010) Traitement symptomatique de la maladie d’Alzheimer et perspectives thérapeutiques. Therapies 65:5, pages 429-437.
Crossref
Crossref
Ejaz Nazir & Muhammad Mushtaq. (2010) A prospective study on the use of rivastigmine transdermal patch in Alzheimer's dementia in a routine clinical setting. Dementia & Neuropsychologia 4:3, pages 245-249.
Crossref
Crossref
Lilian Schafirovits-Morillo & Cláudia Kimie Suemoto. (2010) Severe dementia: A review on diagnoses, therapeutic management and ethical issues. Dementia & Neuropsychologia 4:3, pages 158-164.
Crossref
Crossref
Cristóbal de los Ríos, Javier Egea, José Marco-Contelles, Rafael León, Abdelouahid Samadi, Isabel Iriepa, Ignacio Moraleda, Enrique Gálvez, Antonio G. García, Manuela G. López, Mercedes Villarroya & Alejandro Romero. (2010) Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives. Journal of Medicinal Chemistry 53:14, pages 5129-5143.
Crossref
Crossref
Vesna JelicTaher Darreh-Shori. (2010) Donepezil: A Review of Pharmacological Characteristics and Role in the Management of Alzheimer Disease. Clinical Medicine Insights: Therapeutics 2, pages CMT.S5410.
Crossref
Crossref
Francesco Panza, Vincenzo Solfrizzi, Vincenza Frisardi, Bruno P. Imbimbo, Cristiano Capurso, Alessia D’Introno, Anna M. Colacicco, Davide Seripa, Gianluigi Vendemiale, Antonio Capurso & Alberto Pilotto. (2013) Beyond the neurotransmitter-focused approach in treating Alzheimer’s Disease: drugs targeting β-amyloid and tau protein. Aging Clinical and Experimental Research 21:6, pages 386-406.
Crossref
Crossref
Roger M. Lane & Yunsheng He. (2009) Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE ε4, and hyperhomocysteinemia in neurodegenerative dementias. Medical Hypotheses 73:2, pages 230-250.
Crossref
Crossref
Bernadette McGuinnessDavid Wilson, Stephen Todd & Peter Passmore. (2009) Effective use of drugs in Alzheimer's disease. Practice Nursing 20:Sup1, pages S11-S14.
Crossref
Crossref
Brandy R. Matthews & Bruce L. Miller. 2009. The Behavioral Neurology of Dementia. The Behavioral Neurology of Dementia
56
73
.
Jacqueline Birks, John Grimley Evans, Vasso Iakovidou & Magda Tsolaki. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Ludovico MinatiTrudi Edginton, Maria Grazia Bruzzone & Giorgio Giaccone. (2009) Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review. American Journal of Alzheimer's Disease & Other Dementiasr 24:2, pages 95-121.
Crossref
Crossref
Lori A. Daiello, Brian R. Ott, Kate L. Lapane, Steven E. Reinert, Jason T. Machan & David D. Dore. (2009) Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. The American Journal of Geriatric Pharmacotherapy 7:2, pages 74-83.
Crossref
Crossref
Françoise Forette. (2009) Prévention de la dépendance : le défi de la longévité. Bulletin de l'Académie Nationale de Médecine 193:2, pages 455-471.
Crossref
Crossref
Benjamin Lam, Elizabeth Hollingdrake, James L Kennedy, Sandra E Black & Mario Masellis. (2009) Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Human Genomics 4:2, pages 91.
Crossref
Crossref
Lutz Frölich & Franz Müller-Spahn. 2009. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
22
.
J. J. Jalbert, L. A. Daiello & K. L. Lapane. (2008) Dementia of the Alzheimer Type. Epidemiologic Reviews 30:1, pages 15-34.
Crossref
Crossref
M. -L. Seux, J. de Rotrou & A. -S. Rigaud. (2008) Les traitements de la maladie d’AlzheimerTreatment options for Alzheimer’s disease. PSN 6:2, pages 82-90.
Crossref
Crossref
Changiz Geula, Nicholas Nagykery, Alexander Nicholas & Chuang-Kuo Wu. (2008) Cholinergic Neuronal and Axonal Abnormalities Are Present Early in Aging and in Alzheimer Disease. Journal of Neuropathology & Experimental Neurology 67:4, pages 309-318.
Crossref
Crossref
I. Mateo, J. Llorca, J. Infante, E. Rodríguez-Rodríguez, J. Berciano & O. Combarros. (2008) Gene–gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk. European Journal of Neurology 15:3, pages 219-222.
Crossref
Crossref
Bruno Dubois, Leonardo De Souza, Gilles Allali, Michel Kalafat & Marie Sarazin. (2008) La maladie d’Alzheimer : perspectives thérapeutiques. Bulletin de l'Académie Nationale de Médecine 192:2, pages 333-344.
Crossref
Crossref
Jeffrey L. Cummings, Joan Mackell & Daniel Kaufer. (2008) Behavioral effects of current Alzheimer's disease treatments: A descriptive review. Alzheimer's & Dementia 4:1, pages 49-60.
Crossref
Crossref
Richard J. Goldberg. (2007) Alzheimer’s Disease. Comprehensive Therapy 33:2, pages 58-64.
Crossref
Crossref
Joël Belmin, Renaud Péquignot, Cécile Konrat & Sylvie Pariel-Madjlessi. (2007) Prise en charge de la maladie d'Alzheimer. La Presse Médicale 36:10, pages 1500-1510.
Crossref
Crossref
Nathan Herrmann, Serge Gauthier & Paul G. Lysy. (2007) Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's & Dementia 3:4, pages 385-397.
Crossref
Crossref
David B. Hogan, Peter Bailey, Anne Carswell, Barry Clarke, Carole Cohen, Dorothy Forbes, Malcolm Man‐Son‐Hing, Krista Lanctôt, Debra Morgan & Lilian Thorpe. (2007) Management of mild to moderate Alzheimer's disease and dementia. Alzheimer's & Dementia 3:4, pages 355-384.
Crossref
Crossref
David S Geldmacher. (2007) Acetylcholinesterase inhibitors for Alzheimer’s disease. Aging Health 3:4, pages 483-494.
Crossref
Crossref
S. Gauthier, A. Juby, B. Rehel & R. Schecter. (2007) EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease*. International Journal of Clinical Practice 61:6, pages 886-895.
Crossref
Crossref
Howard H Feldman, Steven Ferris, Bengt Winblad, Nikolaos Sfikas, Linda Mancione, Yunsheng He, Sibel Tekin, Alistair Burns, Jeffrey Cummings, Teodoro del Ser, Domenico Inzitari, Jean-Marc Orgogozo, Heinrich Sauer, Philip Scheltens, Elio Scarpini, Nathan Herrmann, Martin Farlow, Steven Potkin, H Cecil Charles, Nick C Fox & Roger Lane. (2007) Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. The Lancet Neurology 6:6, pages 501-512.
Crossref
Crossref
Jeremy P. Rowland, John Rigby, Adam C. Harper & Rosalind Rowland. (2018) Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol. Advances in Psychiatric Treatment 13:3, pages 178-184.
Crossref
Crossref
Changiz Geula & Nicholas Nagykery. (2007) Butyrylcholinesterase activity in the rat forebrain and upper brainstem: Postnatal development and adult distribution. Experimental Neurology 204:2, pages 640-657.
Crossref
Crossref
Richard A Hansen, Gerald Gartlehner, Kathleen N Lohr & Daniel I Kaufer. (2007) Functional Outcomes of Drug Treatment in Alzheimer???s Disease. Drugs & Aging 24:2, pages 155-167.
Crossref
Crossref
G. Waldemar, B. Dubois, M. Emre, J. Georges, I. G. McKeith, M. Rossor, P. Scheltens, P. Tariska & B. Winblad. (2007) Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology 14:1, pages e1-e26.
Crossref
Crossref
Craig D. Rubin. (2006) The Primary Care of Alzheimer Disease. The American Journal of the Medical Sciences 332:6, pages 314-333.
Crossref
Crossref
Alistair Burns & John O'Brien. (2006) Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. Journal of Psychopharmacology 20:6, pages 732-755.
Crossref
Crossref
João Carlos Machado & Paulo Caramelli. (2006) Treatment of dementia: anything new?. Current Opinion in Psychiatry 19:6, pages 575-580.
Crossref
Crossref
Rafael Blesa, Roger Bullock, Yunsheng He, Howard Bergman, Giuseppe Gambina, Joanne Meyer, Günter Rapatz, Jennifer Nagel & Roger Lane. (2006) Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenetics and Genomics 16:11, pages 771-774.
Crossref
Crossref
Serge Gauthier, Bruno Vellas, Martin Farlow & David Burn. (2006) Aggressive course of disease in dementia. Alzheimer's & Dementia 2:3, pages 210-217.
Crossref
Crossref
Kaj Blennow, Mony J de Leon & Henrik Zetterberg. (2006) Alzheimer's disease. The Lancet 368:9533, pages 387-403.
Crossref
Crossref
Arvid RongveDag Aarsland & Clive Ballard. (2006) Current perspectives in dementia with Lewy bodies. Aging Health 2:3, pages 461-472.
Crossref
Crossref
. (2006) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 21:3, pages 299-306.
Crossref
Crossref
Jacqueline S Birks. (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2016:3.
Crossref
Crossref
T. Dantoine, S. Auriacombe, M. Sarazin, H. Becker, J-J Pere & I. Bourdeix. (2005) Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. International Journal of Clinical Practice 60:1, pages 110-118.
Crossref
Crossref
G. Waldemar, B. Dubois, M. Emre, J. Georges, I. G. McKeith, M. Rossor, P. Scheltens, P. Tariska & B. Winblad. 2006. European Handbook of Neurological Management. European Handbook of Neurological Management
266
298
.
Jacqueline Birks, John Grimley Evans, Vasso Iakovidou & Magda Tsolaki. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.